Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: Results of a randomized, double-blind comparative study

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. C, 1996, Pages 93-101

  Gris, P ^a,b  

^a Centre Hospitalier Cesar de Paepe   (Belgium)

^b Hopital Civil de Jumet   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN;

ADULT; AGED; ARTICLE; BRONCHITIS; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; VOMITING;

EID: 0029839805     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.suppl_c.93     Document Type: Article

References (18)

1. Anthonisen, N. R., Manfreda, J., Warren, C. P. W., Hershfield, E. S., Harding, G. K. M. & Nelson, N. A. (1987). Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 106, 196-204.
2. Aronoff, S. C., Laurent, C. & Jacobs, M. R. (1987). In-vitro activity of erythromycin, roxithromycin and CP-62,993 against common paediatric pathogens. Journal of Antimicrobial Chemotherapy 19, 275-6.
3. Baldwin, D. R., Wise, R., Andrews, J. M., Ashby, J. P. & Honeybourne, D. (1990). Azithromycin concentrations at the sites of pulmonary infection. European Respiratory Journal 3, 886-90.
4. Bright, G. M., Nagel, A. A., Bordner, J., Desai, K. A., Dibrino, J. N., Nowakowska, J. et al. (1988). Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives: a new class of macrolide antibiotics, the azalides. Journal of Antibiotics 41, 1029-47.
5. Cockburn, J., Gibberd, R. W., Reid, A. L. & Sanson-Fisher, R. W. (1987). Determinants of non-compliance with short-term antibiotic regimens. British Medical Journal 295, 814-8.
6. Colcher, I. S. & Bass, J. W. (1972). Penicillin treatment of streptococcal pharyngitis: a comparison of the schedules and the role of specific counselling. Journal of the American Medical Association 222, 657-9.
7. Foulds, G. & Johnson, R. B. (1993). Selection of dose regimens of azithromycin. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 39-50.
8. Foulds, G., Shepard, R. M. & Johnson, R. B. (1990). The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 73-82.
9. Galley, M. S. (1968). To be taken as directed. Journal of the Royal College of General Practitioners 16, 39-44.
10. Gladue, R. P., Bright, G. M., Isaacson, R. E. & Newborg, M. F. (1989). In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 33, 277-82.
11. Greenberg, R. N. (1984). Overview of patient compliance with medication dosing: a literature review. Clinical Therapeutics 6, 592-9.
12. Harf, R., Panteix, G., Guillaumond, B., Sapin, V., Leclercq, M. & Perrin Fayolle, M. (1992). Pulmonary levels of azithromycin after a three-day intake. In Program and Abstracts of the Thirty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, 1992. Abstract 213, p. 146. American Society for Microbiology, Washington, DC.
13. Hoepelman, A. I. M., Sips, A. P., van Helmond, J. L. M., van Barneveld, P. W. C., Neve, A. J., Zwinkels, M. et al. (1993). A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 147-52.
14. Hopkins, S. J. (1994). Clinical toleration and safety of azithromycin in adults and children. Reviews of Contemporary Pharmacotherapeutics 5, 383-9.
15. National Committee for Clinical Laboratory Standards. (1985). Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A4. NCCLS, Villanova, PA.
16. Panteix, G., Guillaumond, B., Harf, R., Desbos, A., Sapin, V., Leclercq, M. et al. (1993). In vitro concentration of azithromycin in human phagocytic cells. Journal of Antimicrobial Chemotherapy 31, 1-4.
17. Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G. et al. (1987). Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrobial Agents and Chemotherapy 31, 1939-47.
18. Sevieri, G., Roggi, G. & Monacci, A. (1993). A comparison between amoxycillin-clavulanic acid and azithromycin in exacerbations of chronic bronchitis sustained by Haemophilus influenzas. Minerva Pneumologica 32, 67-70.